CureVac

CureVac is a Germany-based biopharmaceutical company that develops and commercializes mRNA therapies for the treatment of cancer and infectious diseases.

Business Model:

Revenue: $132.1M

Employees: 501-1,000

Detailed CureVac Information

Geographic Data

CureVac headquarters map

Address: Friedrich-Miescher-Str. 15

City: Tubingen

State: baden-württemberg

Zip: 72076

Country: DE

Financial Info

Stage:

post ipo equity

Raised Last:

$450M

Raised Total:

$2B

Metrics

973,499Website Global Rank

34,843Website Monthly Traffic

Twitter Followers

Description

CureVac is a Germany-based biopharmaceutical company that develops and commercializes mRNA therapies for the treatment of cancer and infectious diseases.

Contact Phone:

Contact Email:

CureVac went public on 8/14/2020 on the NASDAQ

Listed Exchange:
NASDAQ

IPO Date:
8/14/2020

IPO Valuation:
$3B

Ticker Symbol:
CVAC

IPO Price:
$16/share

Amount Raised:
$213M

Live

Opened: -/share

EBITDA -
Total Cash -
Total Debt -
Total Revenue -
Total Profit (Gross) -
PE Ratio -
Announced Date Company Transaction Money Raised
Announced Date Transaction Number of Investors Money Raised Lead Investors
8/2020 IPO $213.3M
7/2020 Debt $84.3M European Investment Bank
5/2010 Series C 1 $34.9M dievini Hopp Biotech Holding
dievini Hopp Biotech Holding
11/2016 Series F 3 $29.5M LBBW Asset Management
Baden-Württembergische Versorgungsanstalt für Ärzte
Landeskreditbank Baden-Württemberg
Baden-Württembergische Versorgungsanstalt für Ärzte
LBBW Asset Management
Baden-Württembergische Versorgungsanstalt für Ärzte
Landeskreditbank Baden-Württemberg
Baden-Württembergische Versorgungsanstalt für Ärzte
7/2020 Venture Round 1 $126M Qatar Investment Authority
Qatar Investment Authority
Qatar Investment Authority
Qatar Investment Authority
2/2021 Post-IPO Equity $450M
7/2020 Debt Financing 1 $84.9M European Investment Bank
European Investment Bank
European Investment Bank
European Investment Bank
1/2003 Series A 2 $2.8M OH Beteiligungen
DH Capital
OH Beteiligungen
DH Capital
1/2006 Series B 2 $26.6M OH Beteiligungen
DH Capital
OH Beteiligungen
DH Capital
9/2020 Grant 1 $298.4M German Federal Ministry of Education and Research (BMBF)
German Federal Ministry of Education and Research (BMBF)
German Federal Ministry of Education and Research (BMBF)
German Federal Ministry of Education and Research (BMBF)
6/2020 Venture Round 1 $340.2M KfW
KfW
KfW
KfW
3/2015 Series E 1 $76M Bill &a; Melinda Gates Foundation
Bill &a; Melinda Gates Foundation
7/2020 Corporate Round 1 $164.6M GlaxoSmithKline
GlaxoSmithKline
GlaxoSmithKline
11/2015 Series F $0 Baillie Gifford
Chartwave
Baillie Gifford
Bill &a; Melinda Gates Foundation
Coppel Family
dievini Hopp Biotech Holding
Northview LifeSciences
Sigma Group
Baillie Gifford
Chartwave
Baillie Gifford
Bill &a; Melinda Gates Foundation
Coppel Family
dievini Hopp Biotech Holding
Northview LifeSciences
Sigma Group
9/2012 Series D 1 $104.4M dievini Hopp Biotech Holding
dievini Hopp Biotech Holding
9/2020 Grant $299M
6/2020 Equity $338M Kreditanstalt fur Wiederaufbau
7/2020 Corporate Round $164.3M GlaxoSmithKline plc
11/2015 Series F 7 $108M Baillie Gifford
Chartwave
Baillie Gifford
Baillie Gifford
Chartwave
Baillie Gifford
Announced Date Name Price
6/2022 Frame Cancer Therapeutics

Employee Departments

Employee States

Uniview Singapore VEID Logo
Uniview Singapore VEID
Revenue: 0 - 100000
Employees:
Industry: Software
Details
Konkuk University Medical Center Logo
Konkuk University Medical Center
Revenue: 0 - 100000
Employees: 51 - 500
Industry: Education
Details
Daemon Technologies Logo
Daemon Technologies
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Blockchain
Details
Ace International Trade Logo
Ace International Trade
Revenue: 0 - 100000
Employees: 11 - 50
Industry: Industrial
Details
An Hòa Communications Logo
An Hòa Communications
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Advertising
Details

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research